Wednesday, 20 Nov 2019

You are here

Breastfeeding Rates Lower in Lupus

It is a common practice for rheumatologists to discuss medication-related teratogenicity and disease implications in case of pregnancy.  Yet, discussion of breastfeeding are often omitted.

Besides being after the fact and little known about the safety of breastfeeding, there are few studies of breastfeeding in lupus and most of these are small in size and have other limitations.  This is in stark contrast with the abundance of published studies on lupus and pregnancy.

Breastfeeding is widely promoted in general population for the benefit of both mother and newborn.  But how safe is breastfeeding in SLE patients?  Do we have reasonable, consistent and accurate recommendations to give our lupus patients?

A cross-sectional study done by Acevedo et al involved a group of physicians from Argentina and compared 36 pregnancies (in 31 SLE patients) with the same number of non-SLE controls to retrospectively assess breastfeeding in lupus.

The number of patients not initiating breastfeeding was higher (19%) in lupus compared to non-lupus mothers (5.6%) who opted not to nurse (p value = 0.07).  For those who breastfed, the average duration of breast feeding was 12 months in no-SLE patient as opposed to 6 months in SLE group (p 0.003).

Interestingly, when it came to reasons for weaning, half of the non-SLE mothers thought they breastfed their children for appropriate amount of time (53%), but SLE patients most often weaned bcause of starting lupus-related medications (41%). Lack of breast milk supply was the second most common cause in both groups (24% and 28% respectively).

Analysis of the medications in SLE group showed that majority of the patient who stopped nursing were on low dose corticosteroids or hydroxychloroquine. The authors did not provide any additional data on type or exact dose of steroids and no additional data on other DMARDs.

The study concluded that breastfeeding duration could potentially be optimized by improved patient education in SLE women intending to become pregnant. 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Part 1:  The “P” in Prednisone stands for Poison...and Other Pearls

Everyone has life hacks.  Years of experience and doing the same things repetitively allow us to figure out little tricks to make life easier. A rat in a maze, finding itself at a dead end, will back up and search for a clearing. If this rat encounters its neighbor, it will transmit that information so the second rat won’t make the same mistake.

Protective Effects of ASA and Vasodilators in Systemic Sclerosis

A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable  cardiovascular outcomes.

Myositis Patients at High Risk of Opportunistic Infections

Among patients with systemic rheumatic diseases, the highest incidence of opportunistic infections was seen in those with polymyositis/dermatomyositis (PM/DM), Taiwanese researchers found.

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Declining Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis Mortality in the USA

Annals of Internal Medicine reports that age-adjusted mortality rates for antineutrophil cytoplasmic autoantibody–associated vasculitides (AAV) have improved over time - with a decline of nearly 2 percent per year in the United States from 1999 to 2017. Nevertheless, long-term outcomes continue to lag behind mortality rates of the general population.